Actively Recruiting
Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis
Led by Fondation Ophtalmologique Adolphe de Rothschild · Updated on 2026-01-20
1200
Participants Needed
12
Research Sites
546 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The recent validation of thrombectomy in addition to thrombolysis with intravenous administration of alteplase suggests a major revolution in the management of acute strokes. This treatment option also opens up a new field of research, making possible the analysis of the clot responsible for intracranial occlusion. Indeed, in about 30% of the cases, the thrombectomy procedure makes it possible to retrieve either partially or completely the clot. Previous studies have analyzed the correlation between the composition of the thrombus and the etiology of stroke. Their discordant results do not yet make it possible to distinguish a particular profile of thrombus according to etiology. Other studies have shown a correlation between the proportion of red blood cells in a thrombus and the likelihood that it is visible in MRI or cerebral scanning. More recently, one study has demonstrated a correlation between the presence of lymphocytes in the thrombus and an atheromatous etiology. The main limitations of these studies are the small number of patients included, the high variability of conservation protocols and the absence of plasma data, which does not allow for research on the correlation between clot composition and plasma biomarkers.
CONDITIONS
Official Title
Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years and older
- Presenting with cerebral infarction following arterial occlusion
- Treated for mechanical thrombectomy (whether performed or not)
- Free, informed, and express consent of the patient or their relatives (emergency inclusion procedure)
- For retrospective patients: thrombus already collected (according to the center's usual practice or for another research project).
You will not qualify if you...
- Patient benefiting from a legal protection measure
- Pregnant or breastfeeding woman
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
CHU de Bordeaux
Bordeaux, France, 33000
Actively Recruiting
2
CHU Caen
Caen, France, 14000
Actively Recruiting
3
Chu Limoges
Limoges, France, 87000
Actively Recruiting
4
CHRU de Nancy
Nancy, France, 54000
Actively Recruiting
5
CHU de Nantes
Nantes, France, 44093
Actively Recruiting
6
Hôpital Lariboisière AP-HP
Paris, France, 75010
Actively Recruiting
7
Centre hospitalier Sainte-Anne
Paris, France, 75014
Actively Recruiting
8
Fondation Ophtalmologique A. de Rothschild
Paris, France, 75019
Actively Recruiting
9
CHU de Rennes
Rennes, France, 35000
Completed
10
Hôpital Foch
Suresnes, France, 92150
Actively Recruiting
11
Hôpital d'Instruction des Armées Sainte-Anne
Toulon, France, 83000
Actively Recruiting
12
CHRU Tours
Tours, France, 37000
Actively Recruiting
Research Team
A
Amélie Yavchitz, MD PhD
CONTACT
J
Jean-Philippe Désilles, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here